Lian B#, Si L, Chi ZH, Sheng XN, Kong Y, Wang X, Tian H, Li K, Mao LL, Bai X, Tang BX, Yan XQ, Li SM, Zhou L, Dai J, Tang XW, Ran FW, Yao S, Guo J, Cui CL*. Toripalimab (anti-PD-1) versus high-dose interferon-α2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial,Annals of Oncology,2022 Oct; 33 (10): 1061-1070.

L. L. Mao#, B. Lian#, C.L. Li, X. Bai, L. Zhou, C. L. Cui, Z. H. Chi, X. N. Sheng, X. Wang, B. X. Tang, X. Q. Yan, S. M. Li, Y. Kong, J. Dai, X. T. Wei, J. Li, R. Duan, H. Y. Xu, X. W. Wu, Y. Yang, F. Z. Cheng, C. Zhang, F. Z. Xia, Z. Pang, J. Guo*, L. Si*. Camrelizumab plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical Trial,JAMA Oncology,doi:10.1001/jamaoncol.2023.1363

Y. Wang#, B. Lian#, L. Si, L. L. Mao, Z. H. Chi, X. N. Sheng, Y. Kong, X. Wang, X. Bai, X. Q. Yan, S. M. Li, B. X. Tang, J. Dai, L. Zhou, X. T. Wei, C. L. Cui*, J. Guo*. Cumulative incidence and risk factors of brain metastasis for acral and mucosal melanoma patients with stages I–III,European Journal of Cancer,2022 Nov;175:196-203.

C. Cui#, B. Lian#, X. Zhang, D. Wu, K. Li, L. Si, Y. Yang, H. Tian, L. Zhou, Z. Chi, X. Sheng, Y. Kong, L. Mao, X. Wang, X. Bai, X. Yan, S. Li, J. Dai, B. Tang, X. Wei, J. E. Gershenwald, C. M. Balch, J. Guo*. An Evidence-Based staging system for mucosal melanoma: A proposal,Ann Surg Oncol,2022 Aug;29(8):5221-5234.

Y. Wang#, B. Lian#, L. Si, Z. Chi, X. Sheng, X. Wang, L. Mao, B. Tang, S. Li, X. Yan, X. Bai, L. Zhou, C. Cui, J. Guo*. Real-world analysis of clinicopathological characteristics, survival rates, and prognostic factors in patients with melanoma brain metastases in China,J Cancer Res Clin Oncol,2021 Sep; 147(9): 2731- 2740.

CSCO黑色素瘤诊疗指南2019、2020、2021、2022版, 参编, 人民卫生出版社, 2022.9

《中国恶性肿瘤整合诊治指南》黑色素瘤分册2022版, 参编, 天津科学技术出版社, 2022.6

卫健委黑色素瘤诊疗规范2022版, 参编, 国家卫生健康委员会, 2022.4

《中国抗肿瘤新药临床研究评述》2020、2021版, 参编, 中国医药创新促进会, 2021.9

优秀带教老师, 优秀带教老师, 第1完成人, 北京大学肿瘤医院, 2022.12

黑色素瘤的临床诊治及转化研究